Impact: This is the first study, to our knowledge, to identify an association between the aberrant DNA methylation of imprinted genes and negative status of the estrogen and progesterone receptors in breast cancer. Furthermore, we describe how variation in methylation of these genes increases from normal breast tissue to benign breast disease to cancer. Our findings may imply an important role for epigenetic disruption of imprinted genes in the development of different breast cancer subtypes. 
Introduction
Genomic imprinting is the epigenetic regulation of genes to enable monoallelic expression according to parental origin, through differential methylation of regions labeled imprinting control regions (ICRs) when established in the germline, or differentially methylated regions (DMRs) when established post-fertilization. Loss of imprinting (LOI) is the loss of this monoallelic expression, and it is commonly the result of disruption of DNA methylation at ICRs and DMRs. LOI is associated with a range of disorders, such as the Beckwith-Wiedemann, Angelman and Prader-Willi syndromes 1, 2 . Imprinted genes have also been implicated in a range of cancers, including those of the breast 3 and ovaries 4 . Their expression has been associated with disease progression, including reduced survival in pancreatic cancer 5 and aggressive prostate cancers 6 . Aberrant methylation of imprinted genes may be an early event involved in neoplastic transformation 7 , and it has been reported that 10% of apparently healthy individuals display LOI of IGF2 8 .
DNA methylation can display stochastic variation, which may facilitate developmental plasticity and adaptation to environments, including that of malignant cells in the tumor microenvironment 9 . This variation can be gene-specific, such as that as observed in the placenta to enable adaptation to environmental challenges throughout pregnancy 10 . A significantly greater level of variation is observed in tumors, which often constitutes shifting in methylation 'boundaries' between CpG islands and shores 11 . Such events may occur early in tumorigenesis, demonstrated by the significantly increased variation observed in cervical cells of normal morphology 12 .
Breast cancers are classified according to the expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).
ER-alpha and PR-A expression are determined by immunohistochemistry, with tumors in which more than 5-10% of cells stain positively classified as positive for expression. HER2 expression is determined by immunohistochemistry, with scores of 0-3 according to intensity of staining, and by fluorescence in situ hybridization (FISH) to detect amplification of the gene.
Activation of these receptor signaling pathways results in cellular proliferation, and they are implicated in the progression of breast and gynecological cancers.
Approximately two-thirds of tumors display expression of at least one of the hormone receptors, and these patients display reduced mortality compared to those who express neither 13 , in part due to the efficacy of endocrine therapies. Triple-negative breast cancers, which account for approximately 12-17% of all cases 14 , are associated with poor prognosis.
The relation between imprinted genes and hormone receptor status in breast cancer has not been well elucidated. Correlations between the methylation of four tumor-suppressor genes and the expression of the hormone receptors has been observed 3 , but similar studies have not been performed for imprinted genes.
Elucidating such a relationship may provide insight into tumorigenesis and the determination of prognostic factors.
In this study, we investigated the aberrant methylation of nine imprinted Variation of DNA methylation in imprinted genes and LINE-1 global methylation were measured, and possible associations between aberrant methylation and the status of the estrogen, progesterone and HER2 receptors in breast cancer patients were identified. Finally, we analyzed the allele-specific expression of the genes in order to establish the relative impact of the aberrant methylation events.
Study populations
The and we integrated these results with methylation levels measured in healthy individuals to identify the relative frequency of aberrant methylation (hypo-and hypermethylation) in the disease states.
In breast tissue, median methylation levels were close to the expected 50%
with the exception of the IGF2 sites, which also displayed greater disparities in the median levels between normal, benign and tumor tissue ( Figure 1 ). Aberrant methylation was frequently observed in invasive breast cancer, observed at IGF2 DMR2 in 59% of patients, IGF2 DMR0 in 38%, DIRAS3 DMR in 36%, GRB10 ICR in 23%, PEG3 DMR in 21%, MEST ICR in 19%, H19 ICR in 18%, KvDMR in 8%, and Table 3 ). Hypomethylation was more common than hypermethylation at all sites except MEST ICR and PEG3 DMR, and was not associated with whether the genes are maternally or paternally expressed.
SNRPN/SNURF ICR in 4% (Supplementary
Among patients with benign breast disease, aberrant methylation was only observed at IGF2 DMR2, which was hypomethylated in 12 of the 26 successfully-analyzed samples. No aberrant methylation was observed in healthy individuals at seven of the imprinted regions, with IGF2 DMR0 hypermethylated in one sample and IGF2 DMR2 hypomethylated in three.
To determine the intra-individual tissue specificity of the methylation changes observed in breast tumors, we analyzed peripheral blood samples taken from the same individuals. Median values for all nine regions were between 39.1 and 53.6%
across the three groups (Supplementary Table 3 ). No samples met the criteria of being hypo-or hypermethylated, indicating that the aberrant methylation events were unique to breast tissue. 
Variation of DNA methylation is significantly greater in breast tissue and blood from patients with invasive breast cancer and benign breast disease

Frequently altered methylation (FAM) and hormone receptor status
Twelve of the invasive tumors analyzed displayed aberrant methylation of at least three of the imprinted regions that were interrogated. We categorized these together as "frequently altered methylation" (FAM 
Monoallelic expression of imprinted genes is maintained in breast tumors
To determine the impact of the observed methylation changes, we examined the allele-specific expression of the genes. Firstly, we genotyped the cancer patients for Monoallelic expression, defined here as >85% of transcripts from a single allele, was almost exclusively retained ( Figure 4) . PEG3 was monoallelically expressed in 17 of 18 patients with normal methylation levels and 5 of 6 patients displaying hypermethylation of the gene ( Figure 4A ). In the other two patients, 71
and 81% of transcripts originated from a single allele. 
GRB10 and IGF2 are differentially expressed in ER-positive tumors
To further examine the relation between hormone receptor status and the expression of imprinted genes, we utilized gene expression microarray data from 302 breast tumor samples, made available through the Walter Reed Army Medical Center.
Expression of seven of the imprinted genes was analyzed between ER-positive (n=199) and ER-negative (n=103) tumors, and between PR-positive (n=153) and PRnegative (n=149) tumors. H19 expression was not covered by the array. GRB10 expression was 1.4-fold lower (p=1.7x10 -10 ) and IGF2 expression was 1.9-fold higher (p=6.0x10 -7 ) in ER-positive tumors (Supplementary Table 5 ). No significant differences were observed by PR status.
Expression of DNA methyltransferases are not associated with hormone receptor status
To investigate how DNA methylation at imprinted regions may be related to estrogen and progesterone receptor status, we utilized gene expression microarray data from 302 breast tumor samples (Supplementary Table 5 ). We observed no significant work has demonstrated that mutations in the DNMT1 gene lead to loss of IGF2 and PEG3 imprinting, with KCNQ1 less susceptible to such changes 27 , and we similarly observed that aberrant methylation of the IGF2 and PEG3 DMRs was substantially more frequent than at the KvDMR (Figure 2A) , although we did not observe an impact upon allele-specific expression. However, we did not observe significantly different expression of DNMT1, DNMT3A or DNMT3B between ER-positive and ERnegative tumors (Supplementary Table 5 ). Our findings may either suggest that the relation between DNA methylation at imprinted loci and ER signaling may be confined to a subset of ER-negative tumors, or that the association is independent of the regulation of DNA methyltransferase expression reported in vitro.
Similar associations between DNA methylation and hormone receptor status have been identified for non-imprinted genes 3, 28 . However, the differential methylation of alleles and roles in regulating proliferation and differentiation make imprinted genes particularly susceptible to driving tumorigenesis. Indeed, changes in the methylation of imprinted genes have been reported in esophageal dysplasia 29 and localized ovarian tumors 30 . As the ER is frequently silenced by promoter methylation in breast tumors 31 We observed increasing variation in DNA methylation from normal breast tissue to benign breast disease to cancer. This finding is consistent with observations made by Teschendorff and colleagues, who suggested increased variability as a marker for early detection of cervical cancer, even being present in cytologically-normal cells of individuals who later developed 12 . Thus, this variability may be a key part of the neoplastic transformation process. It may arise through the shifting of methylation boundaries, rather than gene-specific changes 11 . As we have employed a candidate-gene approach, with comparatively short reads obtained by pyrosequencing, it remains uncertain whether this variability is confined to the interrogated DMRs or whether it may be the result of wider boundary-shifts.
Furthermore, the degree of variation of methylation within the tumors remains unknown. Mosaicism is a well-known phenomenon in cancer, and may provide some explanation for our observations.".
Increased variability in DNA methylation has been proposed as a blood-based marker for ovarian cancer 33 , and we similarly observed significantly increased variation in both the adjusted and unadjusted models at GRB10 ICR, PEG3 DMR and SNRPN/SNURF ICR in peripheral blood from cancer patients. However, the statistical significance may be the product of the tight clustering of values observed in healthy individuals, with mean deviations from median values below 3.5% at all sites.
While group differences may be significant, the value for risk prediction in individuals remains uncertain.
The sites displaying the most frequent aberrant methylation and greatest variation were the two IGF2 DMRs. IGF2 is a widely studied oncogene that stimulates cellular proliferation, and hypomethylation of DMR0 is associated with poor prognosis with colorectal cancer 34 . We observed that hypomethylation of DMR0 was associated with negative ER status, which is itself associated with poor prognosis in breast cancer 13 . The observed frequency of hypomethylation was similar to that reported elsewhere 16 . While loss of IGF2 imprinting in peripheral blood has been suggested as a potential diagnostic marker for colorectal cancer 8 , changes in methylation at DMR0 were specific to the tumors, and we have previously reported a lack of correlation between blood and tumor tissues 18 . This may suggest that peripheral blood cannot serve as a surrogate tissue, although correlations may be gene-specific, as there is evidence that methylation of ATM 35 and targets of ER signaling 36 could be used as blood-based markers of breast cancer risk.
Interestingly, the disruption of methylation did not impact upon allele-specific expression in the tumors, with monoallelic expression almost exclusively retained.
Conversely, our results suggest that GRB10, which is monoallelically expressed in fetal brain tissues and placenta but not in other fetal tissues [37] [38] [39] , may not be imprinted in breast tissue in adult humans. Loss of IGF2 imprinting has been reported in colorectal and ovarian tumors 8, 40 and PEG3 in gynecological cell lines 41 , but we observed >77% of transcripts originating from a single allele in all the tumor samples informative for these genes. Furthermore, our observation of monoallelically-expressed MEST in all seven informative patients is in direct contrast to findings elsewhere of biallelic expression in breast cancer patients 42 . While H19 was biallelically expressed in two patients, methylation of the H19 ICR was not disrupted in these tumors, suggesting an alternative cause of LOI. Hypomethylation of H19 ICR has been correlated with LOI in lung cancer 43 , but there is evidence that the IGF2/H19 competition model does not hold true in colorectal 44, 45 and ovarian 40 tumors. Similarly, a lack of correlation has been observed between hypomethylation of IGF2 DMR0 and LOI in colon and breast tumors 16 , while hypomethylation of IGF2 DMR0 in ovarian serous tumors increases overall expression but does not result in biallelic expression 40 . While the classical model of imprinting suggests that monoallelic expression is the product of differential methylation of the two alleles, this does not appear to hold as strongly in humans as it does in mice. However, it is not clear why the frequency of LOI is lower here than reported elsewhere, as this phenomenon has been reported in primary breast tumors 42, 46 . An alternative explanation for our observations could be that the changes in DNA methylation are confined to a subset of cells in which expression is silenced. As pyrosequencing enables the measurement of the relative abundance of the transcripts from the two alleles, but not their overall quantity, our observations of monoallelic expression being retained may be based upon an inability to detect silencing of the expressed allele in the affected cells.
There have been few studies investigating epigenetic dysregulation in benign breast disease. Although proliferative benign disease is associated with a greater relative risk of developing cancer 47 , we have previously reported no significant difference in methylation at six of the imprinted loci between proliferative and nonproliferative conditions 18 . There is limited evidence of loss of IGF2 imprinting in benign breast disease 48 , and we observed that hypomethylation of IGF2 DMR2 was There is evidence that histologically-normal tissue adjacent to breast tumors can possess genomic alterations seen in the cancer 49 , and therefore it is important to use breast tissue from healthy women as controls in order to accurately identify changes associated with malignant transformation. A further strength was the availability of both DNA and RNA from blood and breast tissue that has enabled us to investigate the specificity of changes in DNA methylation and the effect upon allele-specific expression.
This is the first study, to our knowledge, to identify an association between the aberrant methylation of imprinted genes and hormone receptor status in breast cancer. We have established that 1) aberrant events in the DNA methylation of these imprinted regions are frequent in breast tumors, 2) variation is greater in both breast tissue and in blood from patients with invasive breast cancer than in healthy individuals, and 3) aberrant changes in DNA methylation are associated with hormone receptor status in the tumors. Further work is required to establish whether such methylation changes are the direct result of loss of hormone receptor signaling or are the product of more widespread changes in global DNA methylation. The characteristics of the individuals involved in the study from whom samples of breast tissue and blood were taken. Healthy individuals were matched to the cancer patients by age, ethnicity, BMI, menopausal status and familial history of cancer.
The ages and BMIs are the means of each category. Post-menopausal status includes patients who were surgically post-menopausal, such as following hysterectomy. Familial history of cancer refers to primary and secondary history. For one healthy individual, the familial history was not known. BMI: body mass index. Table 2 . Correlations between DNA methylation of imprinted genes and tumor pathology.
Correlations between aberrant methylation of nine imprinted genes and the tumor and patient characteristics were identified using the Pearson correlation (age at diagnosis) and ANOVA (tumor stage, receptor status and familial history of cancer). 
